Myriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call Transcript Summary
Myriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call Transcript Summary
Adjusted EPS was positive at $0.06.The following is a summary of the Myriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call Transcript:
以下是萬基遺傳公司（MYGN）2024財年第三季度業績會議電話文本摘要：
Financial Performance:
財務表現：
Myriad Genetics reported an 11% revenue growth in Q3 2024 compared to the previous year, demonstrating an improvement in both volume and revenue per test across the portfolio.
Gross profits reached approximately $150 million, with adjusted EBITDA at $14 million.
Adjusted EPS was positive at $0.06.
Despite initial seasonal ordering patterns and impacts from severe weather, the revised 2024 revenue target is around $840 million with an adjusted EPS increase to between $0.12 and $0.14.
萬基遺傳報告稱，與去年同期相比，2024財年第三季度營業收入增長11%，顯示出投資組合中成交量和每項測試的收入均有所改善。
毛利潤達到約15000萬美元，調整後的EBITDA爲1400萬美元。
調整後的每股收益爲正值0.06美元。
儘管受到最初季節性訂購模式和嚴重天氣影響，但修訂後的2024年營業收入目標約爲84000萬美元，調整後的每股收益增至0.12至0.14美元之間。
Business Progress:
業務進展：
Myriad Genetics has fortified its position with enhanced product portfolios such as MyRisk, precise liquid, and Precise MRD, aiming for double-digit growth in Hereditary Cancer testing volumes by 2025.
Investment in cloud-based EMR integrations and digital capabilities aims to streamline provider interactions and improve turnaround times for test results.
New lab facilities in Salt Lake City and South San Francisco have been operational, enhancing testing capabilities and efficiencies.
萬基遺傳通過強化產品組合，如MyRisk、精確液體和Precise MRD，鞏固了其地位，旨在到2025年時將遺傳性癌症測試成交量增長率提升至兩位數。
投資於基於雲的EMR集成和數字能力的目標是簡化提供商互動，改善檢測結果的反饋時間。
鹽湖城和南舊金山的新實驗室設施已經投入運營，提升了檢測能力和效率。
Opportunities:
機會：
Market expansion and product innovation continue to be a strong focus, with developments in prenatal testing, hereditary cancer assessments, and mental health diagnostics through the GeneSight test, despite recent policy changes from UnitedHealthcare.
Regulatory environment remains supportive, with biomarker laws potentially expanding payer coverage for PGx tests.
市場擴展和產品創新繼續是重點，儘管聯合健康保險最近出臺政策變化，但在產前檢測、遺傳性癌症評估以及通過GeneSight測試進行精神健康診斷方面有了新進展。
監管環境仍然支持，生物標記法律可能擴大對個體基因組學檢測的付款範圍。
Risks:
風險：
UnitedHealthcare's recent policy change to restrict access to multi-gene panel PGx testing may significantly impact revenues from the GeneSight product, potentially reducing annual revenue by about $40 million starting from 2025.
UnitedHealthcare最近針對多基因檢測面板的政策變更可能會對GeneSight產品的營業收入產生重大影響，從2025年開始，可能會將年度營業收入減少約4000萬美元。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
